Results of the phase 2 MARCH Study: Oral ATG-010 (Selinexor) plus low dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma (RRMM) previously treated with an immunomodulatory agent (IMiD) and a proteasome inhibitor (PI).

Weijun Fu,Zhongjun Xia,Chengcheng Fu,Wenming Chen,Gang An,Zhen Cai,Baijun Fang,Hongmei Jing,Yongqiang Wei,Jianyu Weng,Chunkang Chang,Lijuan Chen,Sujun Gao,Xiequn Chen,Fei Li,Zhuogang Liu,Jing Liu,Ying Jiao,Aihua Wang,Lugui Qiu

Results of the phase 2 MARCH Study: Oral ATG-010 (Selinexor) plus low dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma (RRMM) previously treated with an immunomodulatory agent (IMiD) and a proteasome inhibitor (PI).

2021

e20002Background: ATG-010 is a novel, oral selective inhibitor of nuclear export inhibiting exportin 1. In preclinical and clinical studies, ATG-010 has demonstrated activity against multiple myelo...

Keywords:

Medicine
Pi
Pharmacology
Dexamethasone
relapsed refractory
Nuclear export signal
Immunomodulatory Agent
Proteasome inhibitor
previously treated
Multiple myeloma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations